drugset
drugset / Trial / NCT02516319

Liver Function Assessment - Feasibility and Dosing Study

NCT02516319 ↗

Terminated 57 enrolled Cardiox Corporation
Non-randomizedSingle-groupOpen-labelDiagnostic

Summary

The purpose of this study is to 1) determine the feasibility of using Cardiox Liver Function Assessment System (LFA) to measure indocyanine green (ICG) clearance; 2) determine an adequate dose based on LFA technology and 3) determine an adequate time period for LFA determination.

Timeline

Start
2012-09
Primary completion
2016-01
Completion
2016-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Indocyanine Green Diagnostic / imaging agent 0.1 mg/kg Other
Subject Indocyanine Green Diagnostic / imaging agent 0.5 mg/kg Other
Subject Indocyanine Green Diagnostic / imaging agent 2.5 mg Other
Subject Indocyanine Green Diagnostic / imaging agent 5 mg Other
Subject Indocyanine Green Diagnostic / imaging agent 7.5 mg Other
Subject Indocyanine Green Diagnostic / imaging agent 10 mg Other

Indications

liver failure